TRDA Entrada Therapeutics, Inc.
Nasdaq · SEC CIK 1689375 · EDGAR
- Bought, last 12 months
- $1.64M 3 purchases by 3 insiders
- Sold, last 12 months
- $15.10M 21 sales by 7 insiders
- Filings on record
- 221 since 2021-11-01, latest 2026-09-09 19:24
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| PARMAR KUSH | Dir, 10% | — | $3.65M |
| MPM BIOVENTURES 2018, L.P. | 10% | — | $3.60M |
| MPM BioVentures 2014, L.P. | 10% | — | $3.60M |
| 5AM Ventures V, L.P. | 10% | — | $3.00M |
| Baker Bros. Advisors (GP) LLC | 10% | $1.35M | — |
| WENTWORTH KORY JAMES | CFO | — | $433.6K |
| Dowden Nathan J | Pres, COO | — | $425.7K |
| Sethuraman Natarajan | Pres, Research, Develop | — | $398.8K |
| BAKER FELIX | 10% | $261.8K | — |
| Zeiher Bernhardt G | Dir | $29.3K | — |
Transactions 229
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-08-18 | 2022-08-16+ | TRDA | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +300 | 20.6K | +1% | +$630 |
| DM | 2022-08-18 | 2022-08-16+ | TRDA | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $13.02 | -600 | 20.2K | -3% | -$7,814 |
| 2022-07-29 | 2022-07-27 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $12.00 | -2,000 | 208.7K | -0.9% | -$24.0K | |
| 2022-06-29 | 2022-06-27 | TRDA | Dowden Nathan J | COO | S - Sale | $13.00 | -7,714 | 64.9K | -11% | -$100.3K | |
| 2022-06-29 | 2022-06-27 | TRDA | Doshi Dipal | Pres, CEO, Dir | S - Sale | $12.00 | -4,000 | 210.7K | -2% | -$48.0K | |
| MI | 2022-06-06 | 2022-06-02+ | TRDA | Baker Bros. Advisors (GP) LLC | 10% | P - Purchase | $6.37 | +40.9K | 364.2K | +13% | +$260.7K |
| MI | 2022-05-24 | 2022-05-20+ | TRDA | BAKER BROS. ADVISORS LP | 10% | P - Purchase | $5.82 | +48.5K | 355.6K | +16% | +$282.4K |
| MI | 2022-05-18 | 2022-05-16+ | TRDA | BAKER BROS. ADVISORS LP | 10% | P - Purchase | $5.99 | +71.9K | 354.7K | +25% | +$430.8K |
| D | 2022-03-03 | 2022-03-01 | TRDA | Sethuraman Natarajan | CSO | A - Grant | $0.00 | +11.6K | 156.3K | +8% | $0 |
| D | 2022-03-03 | 2022-03-01 | TRDA | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +11.0K | 20.5K | +115% | $0 |
| D | 2022-03-03 | 2022-03-01 | TRDA | Doshi Dipal | Pres, CEO, Dir | A - Grant | $0.00 | +30.2K | 214.7K | +16% | $0 |
| D | 2022-03-03 | 2022-03-01 | TRDA | Dowden Nathan J | COO | A - Grant | $0.00 | +11.3K | 72.6K | +18% | $0 |
| D | 2022-03-03 | 2022-03-01 | TRDA | KREHER NERISSA | Chief Medical Off | A - Grant | $0.00 | +10.3K | 15.5K | +199% | $0 |
| D | 2022-01-18 | 2022-01-13 | TRDA | Doshi Dipal | Pres, CEO, Dir | M - OptEx | $1.74 | +10.0K | 184.5K | +6% | +$17.4K |
| 2022-01-13 | 2022-01-12 | TRDA | Crowley John F | Dir | P - Purchase | $9.72 | +5,000 | 5,000 | New | +$48.6K | |
| D | 2021-12-29 | 2021-12-29 | TRDA | KREHER NERISSA | Chief Medical Off | M - OptEx | $2.10 | +5,200 | 5,200 | New | +$10.9K |
| DMI | 2021-11-05 | 2021-11-02 | TRDA | PARMAR KUSH | Dir, 10% | C - Cnv Deriv | — | +3.83M | 649.8K | New | — |
| DI | 2021-11-05 | 2021-11-02 | TRDA | PARMAR KUSH | Dir, 10% | P - Purchase | $20.00 | +250.0K | 1.13M | +28% | +$5.00M |
| DMI | 2021-11-04 | 2021-11-02 | TRDA | ROCHE HOLDING LTD | 10% | C - Cnv Deriv | — | +2.81M | 2.81M | New | — |
| DI | 2021-11-04 | 2021-11-02 | TRDA | Redmile Group, LLC | 10% | P - Purchase | $20.00 | +1.00M | 1.95M | +105% | +$20.00M |
| DI | 2021-11-04 | 2021-11-02 | TRDA | Redmile Group, LLC | 10% | C - Cnv Deriv | — | +954.4K | 954.4K | New | — |
| DMI | 2021-11-04 | 2021-11-02 | TRDA | Schwab Andrew J. | 10% | C - Cnv Deriv | — | +3.83M | 882.4K | New | — |
| DI | 2021-11-04 | 2021-11-02 | TRDA | Schwab Andrew J. | 10% | P - Purchase | $20.00 | +250.0K | 1.13M | +28% | +$5.00M |
| DMI | 2021-11-04 | 2021-11-02 | TRDA | MPM Asset Management Investors BV2014 LLC | 10% | C - Cnv Deriv | — | +4.33M | 4.33M | New | — |
| DI | 2021-11-04 | 2021-11-02 | TRDA | MPM Asset Management Investors BV2014 LLC | 10% | P - Purchase | $20.00 | +100.0K | 4.43M | +2% | +$2.00M |
| DMI | 2021-11-04 | 2021-11-02 | TRDA | MPM BIOVENTURES 2018, L.P. | 10% | C - Cnv Deriv | — | +4.33M | 4.33M | New | — |
| DI | 2021-11-04 | 2021-11-02 | TRDA | MPM BIOVENTURES 2018, L.P. | 10% | P - Purchase | $20.00 | +100.0K | 4.43M | +2% | +$2.00M |
| DMI | 2021-11-04 | 2021-11-02 | TRDA | Foley Todd | Dir, 10% | C - Cnv Deriv | — | +4.33M | 3.82M | New | — |
| DI | 2021-11-04 | 2021-11-02 | TRDA | Foley Todd | Dir, 10% | P - Purchase | $20.00 | +100.0K | 4.43M | +2% | +$2.00M |
Purchase Sale Sale after option exercise All abbreviations